Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications
The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
There has been increasing interest in the role of glutamate in mood disorders, especially given the profound effect of the glutamate receptor antagonist ketamine in improving depressive symptoms in patients with treatment-resistant depression. One pathway by which glutamate alterations may occur in mood disorders involves inflammation. Increased inflammation has been observed in a significant subgroup of patients with mood disorders, and inflammatory cytokines have been shown to influence glutamate metabolism through effects on astrocytes and microglia. In addition, the administration of the inflammatory cytokine interferon-alpha has been shown to increase brain glutamate in the basal ganglia and dorsal anterior cingulate cortex as measured by magnetic resonance spectroscopy (MRS). Moreover, MRS studies in patients with major depressive disorder have revealed that increased markers of inflammation including C-reactive protein correlate with increased basal ganglia glutamate, which in turn was associated with anhedonia and psychomotor retardation. Finally, human and laboratory animal studies have shown that the response to glutamate antagonists such as ketamine is predicted by increased inflammatory cytokines. Taken together, these data make a strong case that inflammation may influence glutamate metabolism to alter behavior, leading to depressive symptoms including anhedonia and psychomotor slowing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation can impact almost all aspects of glutamate neurotransmission (See Haroon and Miller, 2017 for review).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Haroon and Miller, 2017
In the citing paper
“A recent study reported a 38% prevalence of metabolic syndrome in patients with TRD, and it has been estimated that approximately one-third of depressed patients have elevated inflammatory markers.189”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [189]
In the citing paper
“It has been previously described that inflammation leads to glutamate excitotoxicity and synaptic destruction in depression.189”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [189]
In the citing paper
“A recent study reported a 38% prevalence of metabolic syndrome in patients with TRD, and it has been estimated that approximately one-third of depressed patients have elevated inflammatory markers.189”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [189]
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942
Self-citationInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
Self-citationAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Ankarcrona, M., Dypbukt, J. M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S. A., & Nicotera, P. (1995) · Neuron · doi:10.1016/0896-6273(95)90186-8 · Cited by 1,884
Astrocytes, from brain glue to communication elements: the revolution continues
Volterra, A., & Meldolesi, J. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1722 · Cited by 1,770
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Research works printed but not linked: 2
- CDC (2015) Suicide - facts at a glance 2015. Centers for Disease Control, Atlanta, GA, USA
- Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O (2011) A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klinik Psikofarmakoloji Bulteni 21:S183–S184
Cited by
Recognizing Depression from the Microbiota–Gut–Brain Axis
Liang, S., Wu, X., Hu, X., Wang, T., & Jin, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061592 · Cited by 380
Immune targets for therapeutic development in depression: towards precision medicine
Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00368-1 · Cited by 348
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Dooley, L. N., Kuhlman, K. R., Robles, T. F., Eisenberger, N. I., Craske, M. G., & Bower, J. E. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.006 · Cited by 176
Haroon, E., Welle, J. R., Woolwine, B. J., Goldsmith, D. R., Baer, W., Patel, T., Felger, J. C., & Miller, A. H. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0607-1 · Cited by 171
Self-citationLasselin, J., Lekander, M., Benson, S., Schedlowski, M., & Engler, H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00869-2 · Cited by 132
Liu, S., Guo, R., Liu, F., Yuan, Q., Yu, Y., & Ren, F. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s243551 · Cited by 130
“High levels of pro-inflammatory cytokines contribute toward inhibition of the negative feedback function of the HPA axis, improving blood-brain barrier permeability, reducing 5-HT synthesis, and Glu energy system disturbance, which ultimately leads to depression.(49,50) In this study, compared to the healthy microbiot…”
BackgroundShared biological mechanisms of depression and obesity: focus on adipokines and lipokines
Fu, X., Wang, Y., Zhao, F., Cui, R., Xie, W., Liu, Q., & Yang, W. (2023) · Aging · doi:10.18632/aging.204847 · Cited by 124
Goldsmith, D. R., & Rapaport, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00046 · Cited by 122
Haroon, E., Chen, X., Li, Z., Patel, T., Woolwine, B. J., Hu, X. P., Felger, J. C., & Miller, A. H. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0241-4 · Cited by 109
Self-citationKetamine’s effect on inflammation and kynurenine pathway in depression: A systematic review
Kopra, E. I., Mondelli, V., Pariante, C. M., & Nikkheslat, N. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026426 · Cited by 114
Immune mechanisms of depression in rheumatoid arthritis
Brock, J., Basu, N., Schlachetzki, J. C. M., Schett, G. A., McInnes, I. B., & Cavanagh, J. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01037-w · Cited by 112
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Cui, W., Ning, Y., Hong, W., Wang, J., Liu, Z., & Li, M. D. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1306-3 · Cited by 108
Tayab, M. A., Islam, M. N., Chowdhury, K. A. A., & Tasnim, F. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112668 · Cited by 96
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.004 · Cited by 102
Biological Mechanisms of Cancer-Induced Depression
Young, K., & Singh, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00299 · Cited by 99
Gut Inflammation in Association With Pathogenesis of Parkinson’s Disease
Chen, Q.-Q., Haikal, C., Li, W., & Li, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00218 · Cited by 97
Cancer‐related inflammation and depressive symptoms: Systematic review and meta‐analysis
McFarland, D. C., Doherty, M. J., Atkinson, T. M., O’Hanlon, R., BREITBART, W. S., Nelson, C. J., & Miller, A. H. (2022) · Cancer · doi:10.1002/cncr.34193 · Cited by 97
Self-citationLiu, H., Zhang, X., Shi, P., Yuan, J., Jia, Q., Pi, C., Chen, T., Xiong, L., Chen, J., Tang, J., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02768-z · Cited by 92
How Oxidative Stress Induces Depression?
Ji, N., Lei, M., Chen, Y., Tian, S., Li, C., & Zhang, B. (2023) · ASN NEURO · doi:10.1177/17590914231181037 · Cited by 92
Is depression the missing link between inflammatory mediators and cancer?
Polityńska, B., Pokorska, O., Wojtukiewicz, A. M., Sawicka, M., Mysliwiec, M., Honn, K. V., Tucker, S. C., & Wojtukiewicz, M. Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108293 · Cited by 89
Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S. F., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 84
Inflammation and depression but where does the inflammation come from?
Halaris, A. E. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000531 · Cited by 80
Zhang, H., Ding, L., Shen, T., & Peng, D. (2019) · General Psychiatry · doi:10.1136/gpsych-2019-100084 · Cited by 73
Yan, J.-J., Du, G., Qin, X., & Gao, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106092 · Cited by 73
Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders
Czéh, B., & Nagy, S. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00056 · Cited by 70
Li, P., Huang, W., Yan, Y., Cheng, W., Liu, S., Huang, Y., Chen, W., Chen, Y., Gao, Y., Lu, W., et al. (2021) · Medical Science Monitor · doi:10.12659/msm.929027 · Cited by 68
Gruenbaum, B. F., Zlotnik, A. A., Fleidervish, I. A., Frenkel, A., & Boyko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179628 · Cited by 67
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 58
Du, H., Chen, X., Zhang, L., Liu, Y., Zhan, C., Chen, J., Zhang, Y., Yu, Z., Zhang, J., Yang, H., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s211288 · Cited by 55
Sun, Y., Cheng, L., Zeng, X., Zhang, X., Liu, Y., Wu, Z., & Weng, P. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.12.164 · Cited by 51
Sirukumab: A Potential Treatment for Mood Disorders?
Zhou, A. J., Lee, Y. L., Salvadore, G., Hsu, B. L., Fonseka, T. M., Kennedy, S. H., & McIntyre, R. S. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0455-x · Cited by 50
Stress to inflammation and anhedonia: Mechanistic insights from preclinical and clinical models
Boyle, C. C., Bower, J. E., Eisenberger, N. I., & Irwin, M. R. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105307 · Cited by 48
Moschetti, G., Amodeo, G., Paladini, M., Molteni, R., Balboni, G., Panerai, A., Sacerdote, P., & Franchi, S. (2019) · Brain, behavior, and immunity · doi:10.1016/j.bbi.2019.09.012 · Cited by 39
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
Freeman, M. P., Hock, R. S., Papakostas, G. I., Judge, H., Cusin, C., Mathew, S. J., Sanacora, G., Iosifescu, D. V., DeBattista, C., Trivedi, M. H., et al. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001209 · Cited by 48
Increased inflammation predicts nine-year change in major depressive disorder diagnostic status.
Zainal, N. H., & Newman, M. G. (2021) · Journal of Abnormal Psychology · doi:10.1037/abn0000716 · Cited by 48
Almeida, R. F., Ganzella, M., Machado, D. G., Loureiro, S. O., Leffa, D. T., Quincozes‐Santos, A., Pettenuzzo, L. F., Duarte, M. M. M. F., Duarte, T., & Souza, D. O. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.02.013 · Cited by 47
Qin, Q., Xu, X. L., Wang, X., Wu, H., Zhu, H., Hou, Y., Dai, B., Liu, X., & Liu, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-33345-7 · Cited by 46
Abdallah, M. S., Mosalam, E. M., Zidan, A. A., El-Attar, K. S., Zaki, S. A., Ramadan, A. N., & Ebeid, A. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00878-7 · Cited by 42
RetractedXiao, L., Qin, X., Tian, J., Gao, X., Wu, X., Du, G., & Zhou, Y. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111801 · Cited by 42
Puvogel, S., Alsema, A. M., Kracht, L., Webster, M. J., Weickert, C. S., Sommer, I. E., & Eggen, B. J. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01796-0 · Cited by 39
Liu, J., Tian, Y., Yang, S., Zhong, X., He, W., Xu, M., Fang, J., Deng, M., Xu, N., Zeng, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967670 · Cited by 36
Pawłowski, T., Pawlak, D., Inglot, M., Zalewska, M., Marciniak, D. M., Bugajska, J., Janocha‐Litwin, J., & Małyszczak, K. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.190139 · Cited by 36
C-reactive protein and response to lurasidone in patients with bipolar depression
Raison, C. L., Pikalov, A., SIU, C. O., Tsai, J., Koblan, K. S., & Loebel, A. D. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.08.009 · Cited by 33
Microbiota-Gut-Brain Axis in Major Depression: A New Therapeutic Approach
Kim, I. B., Park, S., & Kim, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_10 · Cited by 33
Ho, T. C., Teresi, G. I., Segarra, J. R., Ojha, A., Walker, J. C., Gu, M., Spielman, D. M., Sacchet, M. D., Jiang, F., Rosenberg-Hasson, Y., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.642976 · Cited by 32
New insights into anti-depression effects of bioactive phytochemicals
Zhao, R., Wang, J., Chung, S. K., & Xu, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107566 · Cited by 32
Rengasamy, M. L., Marsland, A. L., Spada, M. L., Hsiung, K. S., Kovats, T., & Price, R. B. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100177 · Cited by 32
Talaee, N., Azadvar, S., Khodadadi, S., Abbasi, N., Pashaki, Z. N. A., Mirabzadeh, Y., Kholghi, G., Akhondzadeh, S., & Vaseghi, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03680-y · Cited by 31
Meléndez, G. P. P., Valero-Jara, V., Acevedo-Hernández, P., & Thomas‐Valdés, S. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2122925 · Cited by 30
Differential Effects of Electroconvulsive Therapy in the Treatment of Major Depressive Disorder
Stippl, A., Kirkgöze, F. N., Bajbouj, M., & Grimm, S. (2020) · Neuropsychobiology · doi:10.1159/000505553 · Cited by 30
Gruenbaum, B. F., Schonwald, A., Boyko, M., & Zlotnik, A. A. (2024) · Cells · doi:10.3390/cells13141228 · Cited by 30
Zhao, C., Ma, H., Yang, L., & Xiao, Y. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s124630 · Cited by 29
Zhong, X., Cao, W., Zhao, H., Chen, L., Cao, J., Wei, L., Tang, Y., Zhong, J., Xiao, X., Zu, X., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.11.001 · Cited by 28
Tao, R., Fu, Z., & Xiao, L. (2019) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.05.002 · Cited by 28
Silva, A. R., Bernardo, A., de Mesquita, M. F., Patto, J. V., Moreira, P. A. M., Silva, M. L., & Padrão, P. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.856216 · Cited by 27
Poletti, S., Mazza, M. G., Vai, B., Lorenzi, C., Colombo, C., & Benedetti, F. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.590095 · Cited by 27
Ortí, J. E. D. L. R., Cuerda‐Ballester, M., Sanchis-Sanchis, C. E., Lajara-Romance, J. M., Navarro-Illana, E., & García-Pardo, M. P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1227431 · Cited by 26
Novel targets for parkinsonism-depression comorbidity
Tizabi, Y., Getachew, B., Csoka, A. B., Manaye, K. F., & Copeland, R. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.004 · Cited by 26
Alozie, E. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608059768115010014 · Cited by 26
Subramaniapillai, M., Carmona, N. E., Rong, C., & McIntyre, R. S. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/rmcintyre · Cited by 25
Quaresma, M. V. L. D. S., Souza, W. T. I., Lemos, V. D. A., Caris, A. V., & dos Santos, R. V. T. (2020) · Nutrients · doi:10.3390/nu12123627 · Cited by 25
Yang, S., Han, J., Ye, Z., Zhou, H., Yan, Y., Han, D., Chen, S., Wang, L., Feng, Q., Zhao, X., et al. (2024) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-024-02579-4 · Cited by 24
Li, X., Hou, R., 石皓, Xuemei, Q. I. N., Wu, X., Wu, X., 田俊生, Gao, X., 杜冠华, & Zhou, Y. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07730-5 · Cited by 24
Taïb, S., Arbus, C., Sauvaget, A., Sporer, M., Schmitt, L., & Yrondi, A. (2018) · Journal of Ect · doi:10.1097/yct.0000000000000477 · Cited by 24
Cytokines as Neuromodulators: Insights From Experimental Studies With Humans and Nonhuman Primates
Martins, D., & Harrison, N. A. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.06.037 · Cited by 23
Kelishadi, M. R., Naeini, A. A., Askari, G., Khorvash, F., & Heidari, Z. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14455 · Cited by 23
Combining inflammatory miRNA molecules as diagnostic biomarkers for depression: a clinical study
Brás, J. P., Pinto, S., von Doellinger, O., Prata, J., Coelho, R. C., Barbosa, M. A., Almeida, M. I., & Santos, S. G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1227618 · Cited by 24
Kuhlman, K. R., Cole, S. W., Irwin, M. R., Craske, M. G., Fuligni, A. J., & Bower, J. E. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.01.004 · Cited by 22
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders
Haroon, E., & Miller, A. H. (2017) · Modern trends in psychiatry · doi:10.1159/000470805 · Cited by 22
Self-citationZhang, X., Wang, H., Kilpatrick, L. A., Dong, T. S., Gee, G. C., Labus, J. S., Osadchiy, V., Beltran-Sanchez, H., Wang, M. C., Vaughan, A., et al. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00134-9 · Cited by 20
Electroacupuncture attenuates LPS-induced depression-like behavior through kynurenine pathway
Wu, X., Hu, R., Jiang, S., Di, Z., Chen, Y., Shi, M., Chen, B., He, K., Qian, K., Guo, Q., et al. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.1052032 · Cited by 20
Arbabi, M., Dezhdar, Z., Amini, B., Dehnavi, A. Z., & Ghasemi, M. (2021) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2021.1991295 · Cited by 19
Mohammad, T. A. M., Mohammad, T. A. M., Salman, D. M., & Jaafar, H. M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2291-7204 · Cited by 19
HIV-associated neurocognitive disorder: key implications of the microbiota-gut-brain axis
Hu, A., Zaongo, S. D., Harypursat, V., Wang, X., Ouyang, J., & Chen, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1428239 · Cited by 19
Modifiable risk factors of dementia linked to excitation-inhibition imbalance
Hafizi, S., & Rajji, T. K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101804 · Cited by 18
Zhao, R., Luo, J., & Xu, B. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106133 · Cited by 18
Effects of infliximab on brain neurochemistry of adults with bipolar depression
Mansur, R. B., Subramaniapillai, M., Lee, Y. L., Pan, Z., Carmona, N. E., Shekotikhina, M., Iacobucci, M., Rodrigues, N. B., Nasri, F., Rosenblat, J. D., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.128 · Cited by 18
Fibromyalgia and Depression in Women: An 1H-NMR Metabolomic Study
Marino, C., Grimaldi, M., Sabatini, P., Amato, P., Pallavicino, A., Ricciardelli, C., & D’Ursi, A. M. (2021) · Metabolites · doi:10.3390/metabo11070429 · Cited by 18
Shiroyama, T., Fukuyama, K., & Okada, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810013 · Cited by 18
Halaris, A. E. (2018) · Future Neurology · doi:10.2217/fnl-2017-0039 · Cited by 18
Abdallah, M. S., Ramadan, A. N., Omara‐Reda, H., Mansour, N. O., Elsokary, M. A., Elsawah, H. K., Zaki, S. A., Mansour, H. E. A., & Mosalam, E. M. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13731 · Cited by 16
RetractedGruenbaum, B. F., Zlotnik, A. A., Oleshko, A., Matalon, F., Shiyntum, H. N., Frenkel, A., & Boyko, M. (2024) · Nutrients · doi:10.3390/nu16060901 · Cited by 15
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 15
Bodnaruc, A. M., Roberge, M., Giroux, I., & Aguer, C. (2024) · Endocrines · doi:10.3390/endocrines5040035 · Cited by 15
Midlife reversibility of early-established biobehavioral risk factors: A research agenda.
Reiss, D., Nielsen, L. O., Godfrey, K. M., McEwen, B. S., Power, C., Seeman, T. E., & Suomi, S. J. (2019) · Developmental Psychology · doi:10.1037/dev0000780 · Cited by 15
Meyyappan, A. C., & Milev, R. V. (2020) · JMIR Research Protocols · doi:10.2196/17223 · Cited by 15
Fenn‐Moltu, S., Deakin, J. F. W., Drake, R., Howes, O. D., Lawrie, S. M., Lewis, S. W., Nikkheslat, N., Walters, J., MacCabe, J. H., Mondelli, V., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.05.005 · Cited by 14
Halaris, A. E., & Leonard, B. E. (2019) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2019.05.005 · Cited by 12
Altered Metabolomics in Bipolar Depression With Gastrointestinal Symptoms
Guo, X., Xiong, Y., Jia, Y., Cui, X., Wu, W., Tian, J., Yang, H., & Ren, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.861285 · Cited by 12
Silva, A. R., Bernardo, A., de Mesquita, M. F., Patto, J. V., Moreira, P. A. M., Silva, M. L., & Padrão, P. (2021) · Trials · doi:10.1186/s13063-021-05146-3 · Cited by 12
The anti-inflammation pharmacodynamics of lithium: Therapy of bipolar disorder
Zhou, Y., Zheng, W., Guo, F., Wu, S., & Zhong, C. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251326942 · Cited by 11
Gökdemir, G. Ş., Şeker, U., Baksi, N., Baylan, M., Demirtaş, B., & Gökdemir, M. T. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06844-5 · Cited by 11
Bashir, Z., Hugerth, L. W., Krog, M. C., Prast‐Nielsen, S., Edfeldt, G., Boulund, F., Schacht, S. R., Tetens, I., Engstrand, L. G., Schuppe‐Koistinen, I., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1324794 · Cited by 11
Treatment-Resistant Depression: Identification and Treatment Strategies
Limandri, B. J. (2018) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20180808-01 · Cited by 11
The Future of Psychoneuroimmunology: Promises and Challenges
Halaris, A. E., Bechter, K., Haroon, E., Leonard, B. E., Miller, A. H., Pariante, C. M., & Zunszain, P. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70554-5_15 · Cited by 11
Self-citation
Metadata
- Authors
- Haroon, E., & Miller, A. H.
- Affiliations
- Emory University (US)
- Corresponding author
- Miller, Andrew H.
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer International Publishing
- Published
- 2016
- Volume
- 31
- Pages
- 173-198
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W2552532188
- Cited by
- 153
- References
- 137
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 18 · 2023: 17 · 2022: 19 · 2021: 21 · 2020: 17 · 2019: 15 · 2018: 16 · 2017: 5 · 2016: 2
- FWCI
- 2.77
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000454)
- National Institute of Mental Health (R21MH077172, R01MH112076, R03MH100273, R01MH107033, R01MH087604, K23MH091254, R21MH105897)
- National Cancer Institute (P30CA138292)
- National Center for Research Resources (UL1RR025008)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- brain glutamate, inflammation, depression, major depressive disorder, inflammatory cytokines, ketamine, treatment-resistant depression, astrocytes, microglia, interferon-alpha, C-reactive protein, basal ganglia, dorsal anterior cingulate cortex, anhedonia, psychomotor retardation, glutamate metabolism
- MeSH terms
- Animals, Depression, Humans, Inflammation, Excitatory Amino Acid Antagonists, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.